Stock Financial Ratios, Dividends, Split History

OKS / ONEOK Partners, L.P. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)3,727.51
Book Value ($M)6,004.87
Book Value / Share82.27
Price / Book0.62
NCAV / Share16.09
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 72,988,252
Common Shares Outstanding2 212,837,980
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.08
Return on Assets (ROA)0.07
Return on Equity (ROE)0.17
Balance Sheet (mrq) ($M)
Quick Ratio0.32
Current Ratio0.40
Income Statement (mra) ($M)
Operating Income1,316.12
Net Income1,072.26
Cash Flow Statement (mra) ($M)
Cash From Operations1,486.78
Cash from Investing-612.59
Cash from Financing-612.59
Identifiers and Descriptors
Central Index Key (CIK)909281
Related CUSIPS
68268N903 68268N953

Split History

Stock splits are used by ONEOK Partners, L.P. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Top Energy Stock Returns to Jefferies Franchise Picks List After Massive Deal

2018-05-07 247wallst
All the Wall Street companies we follow here at 24/7 Wall St. keep a list for their institutional and retail clients of high-conviction stock picks. These are generally the companies they not only like on a longer-term basis, but those that usually have big upside to the assigned target price. Since the beginning of the second quarter, many Wall Street firms have tweaked their lists to account for potential changes in 2018, and one company has added an outstanding stock we feel could have outsized upside. (4-1)

2 Strong Growth Catalysts Mean This High-Yield Stock Could Be Set To Soar

2018-04-30 seekingalpha
It has been a very rough few years for midstream stocks, thanks to a perfect storm of negative factors. (2-0)

5 Dividend Growth Stocks Boosting Shareholder Distributions

2018-04-24 seekingalpha
I use this exercise to monitor performance on existing holdings, and also to uncover hidden gems for further research. (4-0)

Five Dividend Growth Stocks Boosting Shareholder Distributions

2018-04-24 seekingalpha
I use this exercise to monitor performance on existing holdings, and also to uncover hidden gems for further research. (4-0)

Jefferies Has 5 Huge Reasons You Should Buy Energy Stocks Now

2018-04-24 247wallst
After years of underperformance, energy finally is starting to show sector leadership. And of course, just when it does, the president shoots out a tweet last week about OPEC and the current price of oil. This despite the fact that he has cheered U.S. energy independence and our growth in production status as it creates tens of thousands of jobs here at home. Despite the saber-rattling, there’s every indication that higher prices could be here to stay. (2-0)

CUSIP: 68268N103